Roche, DalCor deal

Roche granted DalCor exclusive, worldwide rights to develop and commercialize dalcetrapib. DalCor plans to start a Phase III trial in collaboration with the Montreal Heart Institute in 4Q15 for the small molecule inhibitor of cholesteryl ester transfer protein (CETP) to treat cardiovascular disease. Roche discontinued development of the cardiovascular compound in 2012 due to a “lack of clinically meaningful efficacy” (see BioCentury, May 14, 2012). ...